Our story
- About us
- Latest
- Centres
Our science
- Mission
  - Discover
  - Develop
  - Deliver
- Approaches
- Explore by
Our people
- Researchers
- Governance
- Latest
  
  Sep 10, 2024 - Update
  
  Shaping the future of dementia research: Meet the UK DRI’s newest Emerging Leaders
  
  We are pleased to announce three new UK DRI Emerging Leaders: Dr Maura Malpetti, Dr...
  Learn more Shaping the future of dementia research: Meet the UK DRI’s newest Emerging Leaders
Our partners
- Partnerships
- Initiatives
  - Dementia Trials Accelerator (DTA)
  - CURE-ND
- Latest
  
  Jan 01, 2024 - Feature
  
  Why partner with the UK DRI?
  
  The UK DRI is central to a rich and connected dementia research ecosystem, and we...
  Learn more Why partner with the UK DRI?
Careers
- Join us
  - Vacancies
  - Centres
- Latest
  
  Jan 01, 2024 - Feature
  
  Why join the UK DRI?
  
  By joining the UK DRI you’ll belong to a team of world-class researchers, technical specialists...
  Learn more Why join the UK DRI?
Public Information
- Information
- Dementias
- Movement conditions

Alzheimers Dement

Published Jan 01, 1970

The type-I interferon response potentiates seeded tau aggregation and exacerbates tau pathology.

Authors

Sophie A I Sanford, Lauren V C Miller, Marina Vaysburd, Sophie Keeling, Benjamin J Tuck, Jessica Clark, Michal Neumann, Victoria Syanda, Leo C James, William A McEwan

Read More

Abstract

Signatures of a type-I interferon (IFN-I) response are observed in the post mortem brain in Alzheimer's disease (AD) and other tauopathies. However, the effect of the IFN-I response on pathological tau accumulation remains unclear.

PMID:37849026 | DOI: